Today: 3 July 2026
Compass Group share price rises near 52-week low as UBS rejects ‘AI loser’ worry, Feb 5 update looms
30 January 2026
2 mins read

Compass Group share price rises near 52-week low as UBS rejects ‘AI loser’ worry, Feb 5 update looms

London, Jan 30, 2026, 08:59 GMT — Regular session

  • Compass Group shares gained 0.8% early Friday but remain near a 52-week low
  • UBS calls the recent dip overdone and sticks with its buy rating
  • Attention turns to the first-quarter update and AGM set for Feb. 5

Shares of Compass Group PLC climbed 0.8% to 2,194 pence in early London trading on Friday, pulling back slightly from a recent 52-week low following several days of losses. The stock’s last close was 2,176.5 pence, based on delayed pricing data.

That modest rebound is notable since the FTSE 100 caterer has been moving like a pure sentiment play recently. Investors have been quick to sell off anything linked to office foot traffic, despite the company’s contract structure that typically cushions daily fluctuations.

Next week marks a key checkpoint. Compass will report on first-quarter trading, with investors eager for updates on volumes, pricing, and costs amid easing inflation.

UBS analyst Ivar Billfalk-Kelly says some investors are labeling Compass an “AI loser,” but he calls that worry “overcooked.” He argues any slowdown from job cuts should be minimal in the short term. He maintained a “buy” rating with a 12-month target of 2,985 pence. Billfalk-Kelly highlighted Compass’ solid pricing power, noting U.S. food-away-from-home inflation remains above the price hikes suggested by management. He also cited Aramark as a comparable peer. Proactiveinvestors UK

The real issue isn’t robots serving lunch. It’s whether firms will slash staff and trim office days, and if caterers can keep hiking prices without hurting demand. When brokers mention “forward earnings,” they’re referring to profits forecast for the coming year—the key metric many investors rely on to judge if this selloff has gone too far.

Global markets took another hit from volatility on Thursday, rattled by geopolitical tensions that drove oil prices up. Investors grew uneasy about growth-sensitive stocks, adding to the pressure.

Compass will release its first-quarter trading update at 07:00 GMT on Thursday, Feb. 5. An analyst call is set to follow at 09:00 GMT, according to the company’s invitation.

The company will also conduct its annual general meeting that same morning in London, offering shareholders the opportunity to question management on demand forecasts and capital return plans.

Compass previously guided investors to anticipate roughly 10% growth in underlying operating profit and about 7% organic revenue increase for the upcoming financial year, driven by rising demand in workplace dining and fresh business gains in the U.S.

The near-term risk boils down to this: if the Feb. 5 update reveals softer volumes, weaker net new business, or rising costs from wages and food inputs, the stock may fail to stay above recent lows. Investor chatter about buybacks could shift fast if management hints at prioritizing balance-sheet flexibility.

Traders are holding their breath to see if this early surge will hold up or fade into a short-lived bounce. Eyes are now on Feb. 5, when the first-quarter trading update drops at 07:00 GMT, with the AGM scheduled for later that same morning.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Medicare GLP-1 Bridge Boosts Access, Turns Novo Nordisk (NVO), Lilly (LLY) Obesity Drug Fight to Outcomes
    July 3, 2026, 11:12 AM EDT. Novo Nordisk's NVO Medicare GLP-1 Bridge program started July 1, letting eligible Medicare patients get Wegovy for $50 per month through 2027. That move expands access and helps Novo Nordisk's oral obesity play, which now has more than three million U.S. prescriptions. But Eli Lilly's LLY drugs Zepbound and Foundayo get the same reimbursement, so there's no price edge. Now the competition swings to clinical data and practical differences. Zepbound delivers more weight loss than the Wegovy shot. Foundayo is simpler to dose, but comes with more side effects than Wegovy pills. Novo Nordisk can't lean on pricing and must focus on product results if it wants to keep leading in obesity drugs.
Accenture stock slides 3% as new share award pool wins approval — what investors watch next
Previous Story

Accenture stock slides 3% as new share award pool wins approval — what investors watch next

Imperial Brands share price slips as €900m bond terms land; buyback and dividend dates next for IMB
Next Story

Imperial Brands share price slips as €900m bond terms land; buyback and dividend dates next for IMB

Go toTop